Intestinal injury marker composition and application thereof in preparation of kit for diagnosing RA and / or evaluating RA disease activity
By using human lipopolysaccharide binding protein, intestinal fatty acid binding protein and soluble CD14 molecules as markers, a non-invasive and simple kit was developed, which solved the trauma and complexity of the existing intestinal permeability detection methods, and achieved the right to class Rapid and accurate diagnosis and assessment of rheumatoid arthritis.
Patent Information
- Application Number
- CN202411098512.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
AI Technical Summary
The existing intestinal permeability detection methods have problems such as trauma, complex operation, and long-term consumption, and cannot be used to quickly diagnose autoimmune diseases such as rheumatoid arthritis (RA).
Human lipopolysaccharide binding protein (LBP), human intestinal fatty acid binding protein (I-FABP) and human soluble CD14 molecules as intestinal damage marker compositions, and non-invasive and simple reagents were developed through enzyme-linked immunoassay technology and other methods. Boxes are used to diagnose and evaluate RA condition activities.
It has achieved rapid, accurate and non-invasive diagnosis of intestinal permeability detection in RA patients, with a sensitivity of more than 73% and a specificity of more than 91%. It can effectively distinguish healthy people from active RA patients and early warning of RA disease activities.
Smart Images

Figure CN119001085A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and specifically relates to an intestinal damage marker composition and its application in preparing a kit for diagnosing RA and / or evaluating RA disease activity. Background Art
[0002] Rheumatoid arthritis (RA) is the most common chronic rheumatic disease. Individuals with genetic susceptibility have an imbalanced immune response under the influence of the environment. Among environmental factors, intestinal microorganisms are considered to be a possible factor. In recent years, the role of intestinal microorganisms has received increasing attention. It has been reported that dysbiosis also exists in RA patients, and the intestinal permeability of early RA patients has increased. Before the onset of clinical symptoms in RA patients, microbial imbalance and clinical inflammation of the underlying lamina propria have also been detected in at-risk individuals, leading to the destruction of intestinal barrier integrity. The translocation of microbial products may induce clinical arthritis through further production of immune cells and autoantibodies. Therefore, there is a series of links between intestinal damage and RA.
[0003] Many studies have shown that in addition to intestinal diseases, many non-intestinal diseases such as RA and idiopathic inflammatory myopathy are related to intestinal damage and increased intestinal permeability. Known methods for detecting intestinal permeability include biopsy and molecular probe methods, but the biopsy method is an invasive operation, and the molecular probe method has the disadvantages of complex operation, partial radioactivity, and a long detection process, and cannot be used for rapid diagnosis clinically. Nowadays, there are also some other intestinal permeability evaluation indicators, such as endotoxin, but there are few reports on intestinal permeability indicators related to autoimmune diseases such as RA. This method only requires serum to determine the intestinal permeability of the corresponding patient. It is simple to operate, non-invasive, and easy for patients to accept. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide an intestinal injury marker composition that can effectively diagnose or warn of rheumatoid arthritis activity and has the characteristics of high prediction accuracy and good detection sensitivity.
[0005] The invention provides an intestinal injury marker composition, comprising at least two of human lipopolysaccharide binding protein (LBP), human intestinal fatty acid binding protein (I-FABP) and human soluble CD14 molecule (sCD14).
[0006] The present invention provides the use of the intestinal injury marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule as detection targets in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
[0007] The present invention provides an application of a reagent for detecting the intestinal damage marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
[0008] Preferably, the reagent includes a reagent for detecting the content of at least one of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecule.
[0009] Preferably, when detecting the content of at least one of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecule, the detection method includes enzyme-linked immunosorbent assay technology, protein immunoblotting technology, colloidal gold immunochromatography technology, chemiluminescence immunoassay technology and in situ hybridization technology.
[0010] Preferably, the reagent comprises at least one of the following antibodies: an antibody against human lipopolysaccharide binding protein, an antibody against human intestinal fatty acid binding protein and an antibody against human soluble CD14 molecule.
[0011] Preferably, the antibody comprises a monoclonal antibody and / or a polyclonal antibody.
[0012] Preferably, the antibody comprises a biotin-labeled antibody.
[0013] Preferably, the kit further comprises at least one of the following reagents: enzyme-labeled streptavidin, diluent and washing solution, stop solution and substrate.
[0014] Preferably, the enzyme-labeled streptavidin includes avidin horseradish peroxidase and / or alkaline phosphatase.
[0015] The present invention provides an intestinal injury marker composition, including at least two of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules. The present invention uses RA patients and healthy people as experimental subjects, and detects the contents of LBP, I-FABP and sCD14 respectively. The results show that the three proteins are differentially expressed in RA patients and healthy people, and the expression levels of proteins in RA patients are significantly higher than those in healthy people. The results of sensitivity and specificity analysis show that two or three proteins of LBP, I-FABP and sCD14 are combined as detection targets. The accuracy, sensitivity and specificity of the detection results analyzed by multiple methods are significantly higher than the results of the three proteins detected separately. The detection sensitivity of the combination of three proteins is higher than 73%, the specificity is higher than 91%, and the AUC is 0.9. This shows that the combined evaluation of two or three indicators of LBP, I-FABP and sCD14 can effectively distinguish healthy people from active RA patients, and can quickly and accurately evaluate the activity of rheumatoid arthritis. In addition, the intestinal injury marker composition only requires serum sample detection, is easy to operate, non-invasive, and easy for patients to accept. In addition, the combination of the three biomarkers in this method can effectively warn patients with active RA, with higher accuracy and better sensitivity than a single biomarker. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 This is the result diagram of the differential expression of serum LBP between RA patients and healthy subjects;
[0017] Figure 2 This is the LBP ROC curve analysis result diagram;
[0018] Figure 3 This is the result diagram of differential expression of serum I-FABP between RA patients and healthy subjects;
[0019] Figure 4 This is the result of I-FABP ROC curve analysis;
[0020] Figure 5 This is the result diagram of differential expression of serum sCD14 between RA patients and healthy subjects;
[0021] Figure 6 This is the result of sCD14 ROC curve analysis;
[0022] Figure 7 The figures are the correlation analysis diagrams of intestinal injury markers and inflammatory indicators of patients; (a) the correlation analysis results of sCD14 and inflammatory indicator C-reactive protein; (b) the correlation analysis results of sCD14 and inflammatory indicator erythrocyte sedimentation rate; (c) the correlation analysis results of LBP and inflammatory indicator erythrocyte sedimentation rate;
[0023] Figure 8The figures are the correlation analysis diagrams between intestinal injury markers and disease activity scores; (a) is the correlation analysis result diagram between sCD14 and rheumatoid arthritis disease activity score DAS28-ESR (disease activity score of 28 joints based on erythrocyte sedimentation rate), (b) is the correlation result between LBP, sCD14, I-FABP and disease activity;
[0024] Fig. 9 This is the result diagram of ROC curve analysis of combined indicators;
[0025] Fig.10 This is the multicenter validation result of the combined indicator. DETAILED DESCRIPTION
[0026] The invention provides an intestinal injury marker composition, comprising at least two of human lipopolysaccharide binding protein (LBP), human intestinal fatty acid binding protein (I-FABP) and human soluble CD14 molecule (sCD14).
[0027] In the present invention, the combination of at least two of the human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules has the characteristics of accurate detection results, good detection specificity and high sensitivity in diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis compared with a single intestinal damage marker, and the combination of the three proteins as detection targets has the best effect in terms of detection specificity and detection sensitivity.
[0028] The present invention provides the use of the intestinal injury marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule as detection targets in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
[0029] In the present invention, the detection target is the intestinal injury marker composition as the detection object, and the kit realizes the diagnosis of rheumatoid arthritis and / or the evaluation of rheumatoid arthritis disease activity by detecting the intestinal injury marker composition.
[0030] In the present invention, the method for diagnosing rheumatoid arthritis preferably includes taking the sample to be tested and the serum of healthy people as the detection objects, detecting the content of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules, and comparing whether the detection results show significant differences between the sample to be tested and the serum of healthy people. When the detection results of the sample to be tested and the serum of healthy people are significantly increased, it indicates that the sample to be tested is derived from RA patients; when the detection results of the sample to be tested and the serum of healthy people are similar, it indicates that the sample to be tested is derived from healthy people. The method for evaluating the activity of rheumatoid arthritis is the same as the diagnosis method. When the detection results of the sample to be tested and the serum of healthy people are significantly increased, it indicates that the RA patient from whom the sample to be tested is derived may have rheumatoid arthritis activity; when the detection results of the sample to be tested and the serum of healthy people are similar, it indicates that the RA patient from whom the sample to be tested is derived has no rheumatoid arthritis activity.
[0031] The present invention provides an application of a reagent for detecting the intestinal damage marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
[0032] In the present invention, the reagent preferably includes a reagent for detecting the content of at least one of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules. The reagent realizes the detection of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and / or human soluble CD14 molecules through antigen-antibody specific immune binding reaction. When detecting the content of at least one of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules, the detection method preferably includes enzyme-linked immunosorbent assay technology, protein immunoblotting technology, colloidal gold immunochromatography technology, chemiluminescent immunoassay technology and in situ hybridization technology. The reagent preferably includes at least one of the following antibodies: antibodies against human lipopolysaccharide binding protein, antibodies against human intestinal fatty acid binding protein and antibodies against human soluble CD14 molecules. The antibodies preferably include monoclonal antibodies and / or polyclonal antibodies. The antibodies preferably include biotin-labeled antibodies. The kit preferably also includes at least one of the following reagents: enzyme-labeled streptavidin, diluent and washing solution, stop solution and substrate. The enzyme-labeled streptavidin includes horseradish peroxidase and / or alkaline phosphatase. The method for diagnosing rheumatoid arthritis or evaluating the disease activity of rheumatoid arthritis using the kit is the same as the above technical solution, which will not be described in detail here.
[0033] In one embodiment of the present invention, human lipopolysaccharide binding protein (LBP) ELISA kit, human intestinal fatty acid binding protein (I-FABP) ELISA kit and Human sCD14 ELISA Kit were used to detect the difference in the content of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules in the serum of rheumatoid arthritis patients and healthy people. The results showed that the content of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecules in the two groups was significantly different, and compared with healthy people, the content of the three proteins in the serum of rheumatoid arthritis patients was significantly increased, and the detection sensitivity, specificity and AUC value showed that the combined diagnosis or evaluation results of the three proteins were better than those of a single protein.
[0034] The present invention also provides a detection system for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis, comprising a receiving part, a detection part, an analysis part and an output part connected in sequence;
[0035] The receiving part is used to receive the sample to be tested;
[0036] The detection part is used to detect the content of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules or the expression amount of human lipopolysaccharide binding protein encoding gene, human intestinal fatty acid binding protein encoding gene and human soluble CD14 molecule encoding gene in the sample to be tested collected by the receiving part;
[0037] The analysis part: performs a difference analysis on the test results of the sample to be tested and the test results of the healthy population provided by the system, and obtains the analysis results according to the judgment criteria;
[0038] The output part is used to output the analysis results obtained by the analysis part to the terminal for display.
[0039] In the present invention, the judgment criteria preferably include when the test results of the sample to be tested and the serum of the healthy population show a significant increase, it indicates that the sample to be tested is derived from an RA patient; when the test results of the sample to be tested and the serum of the healthy population show no significant difference, it indicates that the sample to be tested is derived from a healthy person. The method for evaluating the activity of rheumatoid arthritis is the same as the method for diagnosis. When the test results of the sample to be tested and the serum of the healthy population show a significant increase, it indicates that the RA patient from whom the sample to be tested is derived may have rheumatoid arthritis activity; when the test results of the sample to be tested and the serum of the healthy population show no significant difference, it indicates that the RA patient from whom the sample to be tested is derived has no rheumatoid arthritis activity.
[0040] The following is a detailed description of an intestinal injury marker composition provided by the present invention and its application in preparing a kit for diagnosing RA and / or evaluating RA disease activity in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0041] 1. Test supplies
[0042] Human lipopolysaccharide binding protein (LBP) ELISA kit (Wuhan Huamei Biological Company, CSB-E09629h);
[0043] Human intestinal fatty acid binding protein (I-FABP) ELISA kit (Wuhan Huamei Biological Company, CSB-E08024h);
[0044] Human sCD14 ELISA Kit (Lianke Bio, EK1101-96).
[0045] Microplate reader (Labsystems MultiskanMS, Model 352, Finland) full-temperature shaking incubator (Zhejiang Huamei Electric Appliance Manufacturing Co., Ltd.);
[0046] Low-temperature high-speed centrifuge (Thermo Fisher, USA);
[0047] Pipette, gun tip, sample trough, test tube, centrifuge tube, volumetric flask, measuring cylinder, deionized water, etc.
[0048] 2. Experimental Preparation
[0049] Serum: Whole blood samples should be placed at room temperature for 2 hours or at 4°C overnight, then centrifuged at 3500rpm for 10 minutes, and the supernatant can be tested immediately; or the samples can be aliquoted and stored at -20°C or -80°C, but repeated freezing and thawing should be avoided. Thawed samples should be centrifuged again before testing. All reagents and samples should be restored to room temperature (25°C±3°C) before testing.
[0050] Example 1
[0051] LBP and I-FABP detection methods
[0052] 1. Reagent Preparation
[0053] 1.1 Standards
[0054] Take out a standard from the kit and centrifuge at 6000-10000rpm for 30 seconds. Dissolve it with 1ml sample diluent, and use the tip of the gun to repeatedly pipette and beat 5 times at the bottom of the cryotube to help dissolve it. Mix it thoroughly to obtain standard S7 and set it aside. Take 7 1.5ml centrifuge tubes (S0-S6) and arrange them in sequence, and add 250μl sample diluent to each. Pipette 250μl standard S7 into the first centrifuge tube (S6) and mix it gently by blowing. Pipette 250μl from S6 into the second EP tube (S5) and mix it gently by blowing. And so on to perform multiple dilutions of the standard. S0 is the sample diluent.
[0055] 1.2 Washing liquid working solution
[0056] Concentrated detergent is diluted with deionized water at a ratio of 1:25. For example, use a measuring cylinder to measure 240ml of deionized water, pour it into a beaker or other clean container, then measure 10ml of concentrated detergent, add it evenly, stir and mix, and prepare it before use. Concentrated detergent will precipitate salt when stored at low temperature, so it can be heated in a water bath to help dissolve when diluted.
[0057] 1.3 Biotinylated antibody working solution
[0058] The biotin-labeled antibody solution is diluted with the biotin-labeled antibody diluent at a ratio of 1:100. For example, 10 μl of biotin-labeled antibody is added with 990 μl of biotin-labeled antibody diluent, and the mixture is gently mixed. The mixture should be prepared within 10 minutes before use.
[0059] 1.4 Horseradish peroxidase labeled avidin working solution
[0060] Dilute horseradish peroxidase-labeled avidin with horseradish peroxidase-labeled avidin diluent at a ratio of 1:100. For example, add 10 μl of horseradish peroxidase-labeled avidin to 990 μl of horseradish peroxidase-labeled avidin diluent, mix gently, and prepare within 10 minutes before use.
[0061] 2. Detection steps
[0062] 2.1 Move all reagents to room temperature (18-25°C) and equilibrate for at least 30 minutes. Prepare the reagents according to the above method and set aside.
[0063] 2.2 Sample addition: Set up standard wells and sample wells. Add 100 μl of standard or sample to be tested to each well, shake gently to mix, cover with plate sticker, and incubate at 37°C for 2 hours.
[0064] 2.3 Discard the liquid, spin dry, and do not wash.
[0065] 2.4 Add 100 μl of biotin-labeled antibody working solution to each well, cover with a new plate sticker, and incubate at 37°C for 1 hour.
[0066] 2.5 Discard the liquid in the wells, spin dry, and wash the plate 3 times. Soak for 2 minutes each time, 200 μl / well, spin dry.
[0067] 2.6 Add 100 μl of horseradish peroxidase-labeled avidin working solution to each well, cover with a new plate sticker, and incubate at 37°C for 1 hour.
[0068] 2.7 Discard the liquid in the wells, spin dry, and wash the plate 5 times. Soak for 2 minutes each time, 200 μl / well, spin dry.
[0069] 2.8 Add 90 μl of substrate solution to each well and incubate at 37°C in the dark for 15-30 min.
[0070] 2.9 Add 50 μl of stop solution to each well to terminate the reaction.
[0071] 2.10 Within 5 minutes after the reaction is terminated, measure the optical density (OD value) of each well in sequence at a wavelength of 450 nm using an enzyme reader.
[0072] 2.11 Data processing: You can draw a curve after subtracting the S0 well value from the standard and sample values, or use the dual wavelength calibration method for calibration. If duplicate wells are set, the average value should be taken for calculation. Calculate and draw the standard curve with the concentration of the standard as the ordinate (logarithmic coordinate) and the OD value as the abscissa (logarithmic coordinate). According to the sample OD value, the corresponding concentration is found from the standard curve. If the sample is diluted before testing, it needs to be multiplied by the corresponding dilution factor in the final calculation, which is the actual concentration of the sample.
[0073] Example 2
[0074] sCD14 detection method
[0075] 1. Sample dilution
[0076] Normal serum plasma samples need to be diluted 2000 times. Two-step dilution is recommended:
[0077] Step 1: 10 μl sample + 390 μl 1× assay buffer;
[0078] In the second step, 10 μl of the mixed sample diluted in the first step + 490 μl of 1× detection buffer.
[0079] 2. Reagent Preparation
[0080] 2.11× washing liquid
[0081] Pipette 50ml of 20× concentrated washing solution into a 1L measuring cylinder, add distilled water to 1000ml, mix gently to avoid foaming. Transfer to a clean bottle. Store at 2-8℃, 1× washing solution can be kept stable for 30 days.
[0082] 2.21× Assay Buffer
[0083] Pipette 10 ml of 10× concentrated detection buffer into a 100 ml measuring cylinder, add distilled water to 100 ml, mix gently to avoid foaming. Store at 2-8°C. 1× detection buffer is stable for 30 days.
[0084] 2.3 Detection antibody working solution
[0085] Mix thoroughly before diluting. Dilute the concentrated detection antibody 1:100 with 1× detection buffer according to the number of standards and samples to be tested.
[0086] 2.4 Streptavidin working solution
[0087] Mix thoroughly before diluting. Dilute the concentrated streptavidin 1:100 with 1× Assay Buffer, depending on the number of standards and samples to be tested.
[0088] 2.5 Preparation of standard curve
[0089] Centrifuge briefly before opening the tube and reconstitute the standard with distilled water. The reconstitution volume is indicated on the standard label. Vortex gently to ensure thorough mixing. The concentration of the reconstituted standard is 16,000 pg / ml. Let stand for 10 to 30 minutes after reconstitution. Mix thoroughly before diluting. Take 230 μl of the concentrated standard and add 230 μl of 1× assay buffer as the highest concentration of the standard curve (8,000 pg / ml). Add 230 μl of 1× assay buffer to each test tube. Make a 1:1 serial dilution using the high concentration standard. Make sure to mix thoroughly each time you pipette. Use 1× assay buffer as the zero concentration for the standard curve.
[0090] 3. Detection steps
[0091] 3.1 Soak the microplate: Add 300μl 1× washing solution and soak for 30 seconds. Soaking is necessary to obtain ideal experimental results. After discarding the washing solution, pat the microplate dry on absorbent paper. After washing, use the microplate immediately and do not let it dry.
[0092] 3.2 Add standard: Add 100 μl of 2-fold diluted standard to the standard wells. Add 100 μl of 1× detection buffer to the blank wells.
[0093] 3.3 Add sample: Add 100 μl of pre-diluted sample to the sample well.
[0094] 3.4 Add detection antibody: Add 50μl of "detection antibody working solution" to each well. Ensure that steps 2, 3, and 4 are added continuously without interruption. The addition process should be completed within 15 minutes.
[0095] 3.5 Incubation: Seal the plate with a sealing film. Oscillate at 100-300 rpm (to ensure that the solution in each well does not spill and is fully mixed), and incubate at room temperature (25℃±3℃) for 2 hours.
[0096] 3.6 Washing: Discard the liquid, add 300μl of washing solution to each well, and wash 6 times. After each wash, pat dry on absorbent paper. To obtain ideal experimental performance, the residual liquid must be completely removed.
[0097] 3.7 Add enzyme and incubate: Add 100 μl of “streptavidin working solution” to each well.
[0098] 3.8 Incubation: Seal the plate with a new sealing film. Oscillate at 100-300 rpm (to ensure that the solution in each well does not spill and is fully mixed), and incubate at room temperature (25℃±3℃) for 45 minutes.
[0099] 3.9 Washing: Repeat step 3.6.
[0100] 3.10 Add substrate for color development: Add 100 μl of color development substrate TMB to each well, protect from light, and incubate at room temperature (25℃±3℃) for 5-30 minutes.
[0101] 3.11 Add stop solution: Add 100 μl of stop solution to each well. The color changes from blue to yellow. If the color is green or the color change is obviously uneven, please gently tap the plate frame to mix thoroughly.
[0102] 3.12 Test reading: Within 30 minutes, use a microplate reader to perform dual wavelength detection and measure the OD value at the maximum absorption wavelength of 450nm and the reference wavelength of 570nm or 630nm. The calibrated OD value is the measured value at 450nm minus the measured value at 570nm or 630nm. Using only 450nm for measurement will result in a higher OD value and reduced accuracy.
[0103] Example 3
[0104] Differences in LBP between patients with rheumatoid arthritis and healthy subjects
[0105] (1) 28 active RA patients and 23 healthy subjects were enrolled. Peripheral blood was drawn using yellow blood collection tubes and centrifuged at 3500 rpm / min for 10 min. The serum obtained was used to detect LBP levels according to the detection method in Example 1, and the difference in LBP between patients and healthy subjects was analyzed.
[0106] The results showed that the serum LBP level in patients with active RA was significantly increased, indicating that the intestinal permeability of patients with active RA was increased (e.g. Figure 1 ).
[0107] 2) Sensitivity and specificity analysis
[0108] ROC analysis was performed on the research results. IBM SPSS Statistics was used for data analysis and GraphPad Prism 9.0 software was used to draw the graph. The area under the ROC curve was obtained and the LBP concentration with the maximum sensitivity + specificity - 1 value was found as the cut off value.
[0109] The results showed that the area under the ROC curve of LBP was 0.803, the sensitivity was 67.90%, the specificity was 86.96%, and the cut off value was 2.414 μg / ml ( Figure 2 ).
[0110] Example 4
[0111] Differential detection of I-FABP between patients with rheumatoid arthritis and healthy subjects
[0112] (1) 31 patients with active RA and 23 healthy subjects were enrolled. Peripheral blood was drawn using yellow blood collection tubes and centrifuged at 3500 rpm / min for 10 min. The serum was collected and the I-FABP level in the serum was detected according to the method in Example 1. The difference in I-FABP between patients and healthy subjects was analyzed.
[0113] The results showed that the serum I-FABP level in patients with active RA was significantly increased, indicating that the intestinal permeability of patients with active RA was increased (e.g. Figure 3 ).
[0114] (2) Sensitivity and specificity analysis
[0115] ROC analysis was performed on the research results. IBM SPSS Statistics was used for data analysis and GraphPad Prism 9.0 software was used to draw the graph. The area under the ROC curve was obtained and the I-FABP concentration with the maximum sensitivity + specificity - 1 value was found as the cut off value.
[0116] The results showed that the area under the ROC curve of I-FABP was 0.715, the sensitivity was 47.83%, the specificity was 95.65%, and the cut off value was 0.181 ng / ml ( Figure 4 ).
[0117] Example 5
[0118] Differential detection of sCD14 in patients with rheumatoid arthritis and healthy subjects
[0119] (1) 36 active RA patients and 29 healthy subjects were enrolled. Peripheral blood was drawn using yellow blood collection tubes and centrifuged at 3500 rpm / min for 10 min. The serum obtained was tested for sCD14 levels according to the detection method of Example 2, and the difference in sCD14 between patients and healthy subjects was analyzed.
[0120] The results showed that the level of sCD14 in the serum of patients with active RA was significantly increased, indicating that the intestinal permeability of patients with active RA was increased (e.g. Figure 5 ).
[0121] (2) Sensitivity and specificity analysis
[0122] ROC analysis was performed on the obtained studies. IBM SPSS Statistics was used for data analysis and GraphPad Prism 9.0 software was used for plotting. The area under the ROC curve was obtained and the sCD14 concentration with the maximum sensitivity + specificity - 1 value was found as the cut off value.
[0123] The results showed that the area under the ROC curve of sCD14 was 0.771, the sensitivity was 73.91%, the specificity was 78.26%, and the cut off value was 2.24 pg / ml ( Figure 6 ).
[0124] Example 6
[0125] Correlation between LBP, I-FABP, sCD14 and clinical activity and indices
[0126] The results of LBP, I-FABP and sCD14 detected in the above examples were correlated with the disease activity score (DAS28) of RA patients in clinical practice and the inflammatory indicators C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) that reflect disease activity.
[0127] The results showed that sCD14 was significantly positively correlated with the inflammatory markers C-reactive protein and ESR ( Figure 7 In (a) and (b)), LBP was significantly positively correlated with ESR ( Figure 7 (c)). It can be seen that sCD14 and LBP were significantly positively correlated with the inflammatory indicators of patients.
[0128] The results of the correlation analysis between sCD14 and the rheumatoid arthritis disease activity score DAS28-ESR (disease activity score of 28 joints based on erythrocyte sedimentation rate) showed that sCD14 was significantly positively correlated with DAS28-ESR. The patients were grouped according to their disease activity score DAS28-ESR. The results showed that the sCD14 level of patients in the high disease activity group was significantly higher than that of patients in the low and medium disease activity groups, and the LBP level in patients in the high disease activity group was also higher than that in the low and medium disease activity groups. There were also certain differences among patients with different disease activity levels ( Figure 8 ), and therefore, can be used as a method to assess disease activity.
[0129] Example 7
[0130] Combined evaluation of LBP, I-FABP and sCD14
[0131] The evaluation model of active RA (Table 1) was calculated and constructed using the binary logistic regression model with the LBP, I-FABP, and sCD14 variable results obtained in the above example, and a joint ROC analysis was performed.
[0132] Table 1 Coefficients of joint evaluation method
[0133]
[0134] The ROC analysis of the above-mentioned LBP, I-FABP, and sCD14 combined showed that the area under the ROC curve of the combined three biomarkers was significantly higher than that of the single biomarker model ( Fig. 9 ), AUC = 0.900 (P < 0.05), therefore, the diagnostic accuracy of the combined evaluation model was significantly higher than that of the other three univariate diagnostic models. Cut off = 0.536, sensitivity was 73.91%, and specificity was 91.3%.
[0135] Example 8
[0136] Multicenter validation
[0137] Further multicenter validation was conducted in three hospitals, with a total of 105 active RA patients, 17 inactive RA patients, and 29 HCs enrolled, and the above three indicators were again jointly analyzed.
[0138] The results are shown in Table 2. The combined evaluation of LBP, I-FABP, and sCD14 can effectively distinguish healthy people from active RA patients, with AUC = 0.897 (P < 0.0001), cut off = 0.69, sensitivity = 91.8%, and specificity = 76.9% ( Fig.10 ).
[0139] Table 2
[0140]
[0141] Example 9
[0142] Comparison and analysis of several combinations
[0143] The above results confirm that the three different intestinal injury markers have different effects on distinguishing active RA from HC, and different combinations also affect their effectiveness. Therefore, different markers are combined to explore the most effective combination and provide more guidance for clinical practice. Combination analysis of three intestinal injury markers.
[0144] The results are shown in Table 3. The results showed that any combination could significantly distinguish active RA from HC (P < 0.001), however, the combined evaluation of LBP, I-FABP, and sCD14 had the highest AUC, which was better than the combination of any other two markers.
[0145] Table 3
[0146]
[0147] It can be concluded that the combined evaluation of LBP, I-FABP, and sCD14 can effectively distinguish healthy people from active RA patients, and thus can assist in evaluating the disease activity of RA patients, with very high sensitivity and specificity. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. A composition for intestinal injury markers, characterized in that: It includes at least two of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules.
2. Use of the intestinal damage marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule described in claim 1 as detection targets in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
3. Use of a reagent for detecting the intestinal damage marker composition, human lipopolysaccharide binding protein, human intestinal fatty acid binding protein or human soluble CD14 molecule according to claim 1 in the preparation of a kit for diagnosing rheumatoid arthritis and / or evaluating the disease activity of rheumatoid arthritis.
4. The use according to claim 3, characterized in that: The reagents include reagents for detecting the content of at least one of human lipopolysaccharide binding protein, human intestinal fatty acid binding protein and human soluble CD14 molecules.
5. The application according to claim 4, characterized in that: The detection methods include enzyme-linked immunosorbent assay, protein immunoblotting, colloidal gold immunochromatography, chemiluminescent immunoassay and in situ hybridization.
6. The use according to claim 4, characterized in that: The reagent comprises at least one of the following antibodies: an antibody against human lipopolysaccharide binding protein, an antibody against human intestinal fatty acid binding protein and an antibody against human soluble CD14 molecule.
7. The use according to claim 6, characterized in that: The antibodies include monoclonal antibodies and / or polyclonal antibodies.
8. The use according to claim 7, characterized in that: The antibodies include biotin-labeled antibodies.
9. The use according to claim 8, characterized in that: The kit also includes at least one of the following reagents: enzyme-labeled streptavidin, diluent and washing solution, stop solution and substrate.
10. The use according to claim 9, characterized in that: The enzyme in the enzyme-labeled streptavidin includes horseradish peroxidase and / or alkaline phosphatase.
Citation Information
Cited By
Application of human protocadherin 18 as biomarker in preparation of products for diagnosis, auxiliary diagnosis or progress prediction of anti-phospholipid syndrome
CN119667170A
Application of human protocadherin 18 as a biomarker in the preparation of products for diagnosis, auxiliary diagnosis or progression prediction of antiphospholipid syndrome
CN119667170B
